Medical Pharmacology: Chapter 20: Neuromuscular Blocking Drugs -- Module 2: Depolarizing and Non-Depolarizing Neuromuscular Blocking Agents

Chapter 20: Neuromuscular Blocking Drugs — Module 2: Depolarizing and Non-Depolarizing Neuromuscular Blocking Agents
Tier: Tier 3 — Clinical Vignette (11 questions)

1. A 38-year-old man presents with a 3-week history of ascending limb weakness and areflexia consistent with Guillain-Barré syndrome. He has developed respiratory failure requiring intubation. He is fully alert and anxious. His serum potassium is 4.1 mEq/L. The emergency medicine physician reaches for succinylcholine for rapid sequence intubation. Which of the following correctly identifies the pharmacological risk and the appropriate RSI strategy for this patient?

A) Succinylcholine is safe in this patient because his serum potassium is within normal limits at 4.1 mEq/L, and the dangerous hyperkalemia associated with succinylcholine in neurological disease requires a baseline potassium above 5.0 mEq/L to produce a life-threatening additive surge; a normal baseline potassium provides adequate buffer against the 0.5 mEq/L rise produced by succinylcholine.
B) Succinylcholine is contraindicated in this patient — Guillain-Barré syndrome produces lower motor neuron and peripheral nerve demyelination with functional denervation of skeletal muscle; over 3 weeks of progressive denervation, extrajunctional nicotinic acetylcholine receptors have upregulated across the entire muscle surface; succinylcholine will trigger massive potassium efflux from these upregulated extrajunctional receptors, potentially raising serum potassium by 5 to 10 mEq/L and precipitating ventricular fibrillation; rocuronium 1.2 mg/kg with sugammadex 16 mg/kg immediately available is the correct RSI strategy.
C) Succinylcholine is relatively safe in Guillain-Barré syndrome because the demyelinating process in this condition affects Schwann cells rather than the motor axon itself, preserving axonal continuity and the trophic signals that prevent extrajunctional receptor upregulation; only axon-transecting injuries such as spinal cord trauma or peripheral nerve crush produce the receptor upregulation that creates hyperkalemia risk.
D) Succinylcholine is appropriate in this patient because 3 weeks is insufficient time for extrajunctional receptor upregulation to reach the dangerous threshold — receptor density does not rise to levels associated with life-threatening hyperkalemia until at least 8 to 12 weeks after the onset of neurological injury, making this patient's 3-week course safe for a single RSI dose.
E) Succinylcholine should be avoided in this patient not because of hyperkalemia risk but because Guillain-Barré syndrome is associated with autonomic instability, and succinylcholine's vagomimetic effects combined with existing autonomic dysregulation create a high risk of refractory bradycardia and asystole that cannot be prevented by atropine pretreatment; rocuronium is preferred because it has no direct cardiac muscarinic activity.

ANSWER: B

Rationale:

This question asked you to identify the contraindication to succinylcholine in a patient with established Guillain-Barré syndrome and recommend the appropriate RSI alternative. Guillain-Barré syndrome (GBS) produces demyelination and often axonal injury of peripheral motor nerves, creating a functional denervation state in the innervated skeletal muscles. The critical pharmacological consequence is extrajunctional nicotinic acetylcholine receptor upregulation: in response to the loss of normal motor nerve trophic signaling and impulse traffic, muscle fibers upregulate fetal-type nAChRs across the entire sarcolemmal surface beyond the normal junctional zone. This process is established within days to weeks of the neurological injury. This patient has had 3 weeks of progressive ascending weakness — sufficient time for significant extrajunctional receptor upregulation throughout the affected and atrophying muscle groups. Administration of succinylcholine to this patient will activate all of these receptors simultaneously, releasing massive amounts of intracellular potassium and potentially raising serum potassium by 5 to 10 mEq/L — sufficient to produce life-threatening ventricular arrhythmias despite a normal baseline potassium. The safe RSI strategy is rocuronium 1.2 mg/kg with sugammadex 16 mg/kg immediately available; rocuronium is a non-depolarizing agent that does not trigger this potassium release mechanism.

Option A: Option A is incorrect because the risk is not determined by baseline potassium — the danger is the acute surge of 5 to 10 mEq/L from extrajunctional receptor activation, which produces lethal arrhythmias regardless of the starting potassium level.
Option C: Option C is incorrect because GBS causes not only demyelination but in many cases axonal injury as well, and even demyelination with functional denervation is sufficient to trigger extrajunctional receptor upregulation; axonal continuity does not prevent the receptor changes if normal impulse traffic and trophic signals are disrupted.
Option D: Option D is incorrect because extrajunctional receptor upregulation does not require 8 to 12 weeks — it develops within days to weeks of the denervating injury, and 3 weeks of progressive GBS constitutes an established and sufficient window for dangerous receptor changes.
Option E: Option E is incorrect because while GBS does cause autonomic instability and succinylcholine does have vagomimetic properties, the primary and life-threatening contraindication in this patient is hyperkalemia from extrajunctional receptor upregulation, not autonomic instability from vagomimetic effects.

2. A 24-year-old construction worker is brought to the emergency department after a nail gun injury to his left eye. Examination reveals a full-thickness laceration of the globe with vitreous prolapse. He ate lunch 2 hours ago. He is in moderate pain and anxious, and requires urgent surgical repair under general anesthesia. The anesthesiologist must decide on an intubation strategy that addresses both the aspiration risk from the full stomach and the risk to the injured eye. Which of the following best represents the pharmacologically sound approach to this clinical dilemma?

A) Succinylcholine 1.5 mg/kg is the only acceptable agent — the aspiration risk from a full stomach in an anxious, in-pain patient is the dominant life-threatening concern, and succinylcholine's unparalleled speed of onset (45 to 60 seconds) and ultra-short duration are essential safety properties; the intraocular pressure increase from succinylcholine is a theoretical concern with no documented cases of vitreous extrusion attributable to the drug in the absence of other factors such as coughing or straining at intubation.
B) The procedure should be delayed until full gastric emptying can be confirmed by bedside ultrasound, which takes approximately 4 to 6 hours; during this period the patient should receive proton pump inhibitor therapy and remain nil per os; once gastric emptying is confirmed, inhalational induction without any neuromuscular blocking agent eliminates both the aspiration and the intraocular pressure risks simultaneously.
C) Ketamine 2 mg/kg intravenously without any neuromuscular blocking agent is the correct approach — ketamine maintains airway reflexes and spontaneous ventilation, eliminates aspiration risk through preserved laryngeal tone, and its sympathomimetic properties increase systemic blood pressure, which counteracts the intraocular pressure rise from succinylcholine that would otherwise be present; no paralysis is required when this combination is used.
D) Succinylcholine should be administered at a defasciculating dose of 0.1 mg/kg followed 3 minutes later by the full intubating dose of 1.5 mg/kg — the pre-treatment non-depolarizing dose prevents the fasciculations responsible for the intraocular pressure increase, eliminating the ocular risk while preserving succinylcholine's rapid onset for aspiration protection.
E) Rocuronium 1.2 mg/kg with sugammadex 16 mg/kg immediately drawn up and available is the preferred approach — it achieves intubating conditions within 45 to 60 seconds comparable to succinylcholine, avoids the transient intraocular pressure increase associated with succinylcholine-induced extraocular muscle contraction, and provides the critical safety net of immediate reversal within 3 minutes if intubation fails and the airway must be abandoned; careful induction technique to prevent coughing and bucking remains essential regardless of which agent is chosen.

ANSWER: E

Rationale:

This question asked you to apply pharmacological reasoning to an open globe injury with a concurrent full stomach aspiration risk. This is a recognized clinical dilemma in anesthetic practice. Succinylcholine causes a transient increase in intraocular pressure (IOP) through sustained contraction of extraocular muscles producing external globe compression, and in an eye with a full-thickness laceration and vitreous prolapse, this pressure rise theoretically risks extrusion of intraocular contents. While evidence that succinylcholine alone causes vitreous extrusion in humans is not definitive, the concern is sufficient to make a non-depolarizing alternative preferable when one exists. Rocuronium at 1.2 mg/kg achieves intubating conditions within 45 to 60 seconds — onset comparable to succinylcholine — and does not cause extraocular muscle contraction or IOP elevation. The availability of sugammadex 16 mg/kg provides the rescue option for a failed intubation that was previously unavailable with non-depolarizing agents, eliminating the historical reason succinylcholine was considered irreplaceable for full-stomach intubation. Meticulous induction technique to prevent coughing, straining, and laryngoscopy-induced IOP spikes remains essential regardless of agent chosen.

Option A: Option A is incorrect because while the clinical evidence for succinylcholine-induced vitreous extrusion is incomplete, the availability of rocuronium-sugammadex as a pharmacologically equivalent alternative means there is no clinical justification for accepting even the theoretical IOP risk in a patient with an open globe when an alternative exists.
Option B: Option B is incorrect because delaying surgery for gastric emptying in an acute open globe injury is not appropriate — the vitreous prolapse requires urgent repair, and a 4 to 6 hour delay increases infection risk and worsens outcome; the aspiration risk must be managed, not avoided by delay.
Option C: Option C is incorrect because ketamine does not reliably prevent aspiration — it does not eliminate passive regurgitation risk in a full stomach patient, and airway reflexes may be inadequate to prevent aspiration of regurgitated material; ketamine is not an alternative to RSI technique in a full stomach patient.
Option D: Option D is incorrect because defasciculation pretreatment with a small non-depolarizing dose does not reliably prevent succinylcholine-induced IOP elevation — the IOP rise from extraocular muscle contraction is not fully prevented by this technique, and the evidence for benefit is limited.

3. A 71-year-old woman with Child-Pugh class C hepatic cirrhosis from alcohol-related liver disease is scheduled for elective umbilical hernia repair. She has a serum albumin of 2.1 g/dL, INR of 2.4, and moderate ascites. The anesthesiologist needs neuromuscular blockade for intubation and surgical relaxation for a procedure expected to last 90 minutes. Rocuronium 0.6 mg/kg was used at the last procedure 2 years ago and produced block lasting over 2 hours. Which agent and dose strategy is most appropriate for this patient?

A) Cisatracurium 0.15 mg/kg is the most appropriate choice — its elimination by Hofmann degradation is entirely independent of hepatic metabolic capacity, biliary excretion, and plasma protein synthesis, making its pharmacokinetics predictable in a patient with severe hepatic failure regardless of albumin, INR, or ascites; duration will be reliable and reversal with neostigmine at adequate train-of-four recovery or sugammadex at any depth will be standard if aminosteroid reversal were needed, but since cisatracurium is a benzylisoquinolinium, neostigmine at adequate recovery is the reversal option.
B) Rocuronium 0.3 mg/kg should be used — reducing the dose by 50% from the standard 0.6 mg/kg normalizes the duration in hepatic failure because the prolongation is linearly proportional to dose; at half the standard dose, the 2-hour duration seen previously will be shortened to approximately 60 minutes, matching the planned procedure length.
C) Pancuronium 0.1 mg/kg is appropriate because its predominantly renal elimination makes it independent of hepatic function; in a patient with hepatic failure, renal-pathway agents are preferable because the kidneys remain intact and provide a reliable alternative clearance route that maintains predictable drug duration.
D) Succinylcholine should be used for intubation and repeated boluses of succinylcholine administered every 5 to 10 minutes throughout the 90-minute procedure for maintenance of relaxation — hepatic failure reduces pseudocholinesterase synthesis, which prolongs succinylcholine duration toward 20 to 30 minutes per dose, transforming succinylcholine into an effective intermediate-duration agent that is ideal for this length of procedure.
E) Vecuronium 0.1 mg/kg is preferred over rocuronium in hepatic failure because vecuronium has a lower volume of distribution and does not depend on biliary excretion, allowing it to be primarily eliminated by renal tubular secretion that is unaffected by this patient's liver disease; its shorter half-life in this setting makes it more predictable than rocuronium.

ANSWER: A

Rationale:

This question asked you to select the optimal neuromuscular blocking agent for a patient with severe hepatic failure, integrating the elimination pathways of the available agents. This patient has Child-Pugh class C cirrhosis — severely impaired hepatic synthetic and metabolic function evidenced by low albumin, elevated INR, and ascites. The prior experience of over 2-hour rocuronium duration confirms that hepatic clearance of aminosteroid agents is markedly impaired. Cisatracurium is the rational choice because its elimination proceeds via Hofmann degradation — spontaneous, non-enzymatic chemical breakdown at physiological pH and temperature — a pathway that is entirely independent of hepatic blood flow, hepatocellular enzyme activity, biliary excretion, or plasma protein binding. In a patient with Child-Pugh class C disease, cisatracurium duration is predictable and essentially normal while all aminosteroid agents (rocuronium, vecuronium, pancuronium) will have prolonged and variable duration. At a standard intubating and maintenance dose of 0.15 mg/kg, cisatracurium provides reliable 40 to 60 minute intermediate duration in this patient. Reversal with neostigmine at adequate train-of-four recovery is appropriate since cisatracurium is a benzylisoquinolinium not reversible by sugammadex.

Option B: Option B is incorrect because halving the rocuronium dose does not proportionally normalize its duration in severe hepatic failure — the prolongation is not simply dose-proportional but reflects impaired clearance; even a reduced dose will have unpredictable prolonged duration in Child-Pugh class C disease.
Option C: Option C is incorrect because pancuronium is approximately 80% renally eliminated unchanged, making it dependent on renal function rather than hepatic function — but this patient's cirrhosis may produce hepatorenal syndrome, and pancuronium's vagolytic and sympathomimetic cardiovascular effects make it inappropriate in most modern practice; cisatracurium is the superior organ-failure choice.
Option D: Option D is incorrect because using repeated succinylcholine boluses for a 90-minute procedure is not appropriate practice — repeated dosing risks Phase II block, accumulation, and unpredictable prolonged paralysis; and while hepatic failure does reduce pseudocholinesterase synthesis and can prolong succinylcholine duration, the variability is not controllable enough for a maintenance strategy.
Option E: Option E is incorrect because vecuronium is not primarily eliminated by renal tubular secretion — it undergoes hepatic deacetylation to the 3-desacetyl active metabolite; in hepatic failure, both parent drug metabolism and metabolite generation are affected, making vecuronium at least as unpredictable as rocuronium in this setting.

4. A 58-year-old man has been receiving a vecuronium infusion at 0.8 mcg/kg/min for 10 days in the medical ICU for ventilator synchrony during treatment of severe pneumonia-related acute respiratory distress syndrome (ARDS). His creatinine has risen from 1.1 to 4.6 mg/dL over the past 4 days, consistent with acute kidney injury. The intensivist discontinues the vecuronium infusion, but 36 hours later the patient has a train-of-four count of zero with no post-tetanic responses. Which of the following correctly identifies the pharmacological mechanism of this prolonged block and the best strategy going forward?

A) Vecuronium itself has accumulated in the plasma because its biliary excretion is partially dependent on a renal cofactor that becomes deficient in acute kidney injury, effectively converting vecuronium to a renally eliminated compound at high infusion doses; the prolonged block will resolve over 24 to 48 hours as the vecuronium molecule itself is slowly excreted by the intact but reduced renal tubular secretion capacity.
B) The prolonged block reflects laudanosine accumulation — vecuronium undergoes a minor Hofmann elimination pathway that generates laudanosine at high infusion doses, and with acute kidney injury impairing laudanosine renal clearance, plasma concentrations have reached levels sufficient to activate nicotinic acetylcholine receptors at the neuromuscular junction independently of the parent vecuronium molecule.
C) The prolonged block is caused by accumulation of 3-desacetyl-vecuronium, the pharmacologically active hepatic metabolite of vecuronium that retains approximately 50% of the parent compound's neuromuscular blocking potency and is eliminated by renal excretion; acute kidney injury has prevented its clearance, allowing it to accumulate to concentrations that sustain profound block for days after infusion discontinuation; future ICU paralysis should use cisatracurium, whose Hofmann elimination produces no renally cleared active metabolite.
D) The block reflects Phase II transition — after 10 days of continuous vecuronium infusion, the nicotinic acetylcholine receptors at the neuromuscular junction have undergone structural remodeling analogous to desensitization block, transitioning from competitive antagonism to a covalent conformational change that is not reversible by sugammadex or neostigmine and requires days to weeks of receptor turnover for recovery.
E) The prolonged block is caused by depletion of plasma cholinesterase from 10 days of ICU illness — without adequate cholinesterase to hydrolyze acetylcholine at the neuromuscular junction, the elevated synaptic acetylcholine paradoxically maintains receptor desensitization; vecuronium acts synergistically with the high acetylcholine to sustain block at concentrations that would normally produce only moderate paralysis in a patient with normal cholinesterase activity.

ANSWER: C

Rationale:

This question asked you to identify the specific mechanism of prolonged vecuronium block in an ICU patient who has developed acute kidney injury. Vecuronium undergoes hepatic deacetylation to three metabolites, the most clinically significant of which is 3-desacetyl-vecuronium. This active metabolite retains approximately 50% of the neuromuscular blocking potency of the parent compound and — critically — is eliminated by renal excretion. In a patient with normal renal function, this metabolite is efficiently cleared. In a patient with acute kidney injury, however, the 3-desacetyl metabolite cannot be excreted and accumulates progressively throughout the infusion period. After 10 days of vecuronium infusion in a patient whose creatinine has risen to 4.6 mg/dL, the metabolite has accumulated to concentrations sufficient to sustain profound neuromuscular block for days beyond infusion discontinuation — consistent with the 36-hour post-infusion train-of-four count of zero observed. This is the well-documented mechanism underlying the clinical reports of prolonged ICU paralysis with vecuronium, and is the primary pharmacological reason cisatracurium replaced vecuronium for long-term ICU paralysis. Cisatracurium's elimination via Hofmann degradation produces laudanosine (which has CNS activity at high concentrations but no NMJ activity) but generates no renally excreted active neuromuscular blocking metabolite.

Option A: Option A is incorrect because vecuronium's biliary excretion is not dependent on a renal cofactor; the mechanism of accumulation in renal failure is specifically active metabolite accumulation, not parent drug conversion to a renally eliminated form.
Option B: Option B is incorrect because vecuronium does not undergo significant Hofmann elimination and does not produce laudanosine; laudanosine is a degradation product of atracurium and cisatracurium, not of aminosteroid agents.
Option D: Option D is incorrect because non-depolarizing block does not involve covalent receptor remodeling analogous to desensitization; vecuronium is a competitive reversible antagonist, and the prolonged block in this case is pharmacokinetic (metabolite accumulation), not a receptor-level structural change.
Option E: Option E is incorrect because vecuronium is not dependent on cholinesterase for its mechanism of action, and plasma cholinesterase depletion does not cause receptor desensitization; this mechanism describes succinylcholine pharmacology, not competitive non-depolarizing block.

5. A 31-year-old woman at 34 weeks gestation requires emergent cesarean delivery under general anesthesia for placental abruption. She has been receiving magnesium sulfate at 2 g/hour intravenously for 6 hours for preeclampsia with severe features, and her serum magnesium level is 5.8 mg/dL (therapeutic range 4 to 7 mg/dL). The obstetric anesthesiologist plans rapid sequence intubation followed by rocuronium maintenance. Which of the following best describes the modifications to the neuromuscular blocking drug regimen required by the patient's magnesium status, and what monitoring is essential?

A) No modifications to the neuromuscular blocking regimen are required — therapeutic magnesium levels (4 to 7 mg/dL) do not affect neuromuscular junction pharmacology in pregnant patients because progesterone upregulates presynaptic calcium channel expression during pregnancy, counteracting magnesium's calcium channel inhibition and restoring normal acetylcholine release kinetics.
B) Succinylcholine dose should be increased to 2.0 mg/kg to overcome magnesium-mediated competitive antagonism at the nicotinic receptor — because magnesium occupies postjunctional nAChRs at therapeutic serum concentrations, a higher succinylcholine dose is needed to displace the magnesium and achieve reliable depolarizing block within the RSI window.
C) Rocuronium should be replaced with succinylcholine for both induction and maintenance, administered as a continuous infusion at 10 mg/min — magnesium prolongs the duration of all non-depolarizing agents unpredictably, making safe maintenance impossible; succinylcholine infusion avoids this problem because magnesium does not affect succinylcholine pharmacokinetics in pregnant patients receiving therapeutic levels.
D) Both succinylcholine and rocuronium doses should be reduced — magnesium potentiates neuromuscular block from both agents by reducing presynaptic acetylcholine release through calcium channel competition, lowering the effective concentration needed to achieve any given depth of block; rocuronium maintenance doses should be reduced and dosing intervals extended; quantitative train-of-four monitoring is essential throughout the case and postoperatively, as residual block from potentiated rocuronium in the context of ongoing magnesium infusion increases the risk of respiratory failure at extubation.
E) Only the rocuronium maintenance dose requires adjustment — succinylcholine for RSI is used at the standard 1.5 mg/kg dose without modification because its mechanism of depolarizing block is independent of presynaptic acetylcholine release and therefore unaffected by magnesium's presynaptic calcium channel inhibition; the potentiation applies exclusively to non-depolarizing competitive agents.

ANSWER: D

Rationale:

This question asked you to apply the pharmacological interaction between magnesium and neuromuscular blocking agents to a specific obstetric clinical scenario requiring practical dose adjustments. Magnesium potentiates neuromuscular block from both succinylcholine and non-depolarizing agents through a presynaptic mechanism: magnesium ions compete with calcium at presynaptic voltage-gated calcium channels at the motor nerve terminal, reducing calcium influx per action potential and thereby reducing the quantal content of acetylcholine released per stimulus. For succinylcholine, reduced acetylcholine release means that the depolarizing drug acts against a backdrop of already-reduced synaptic acetylcholine competition, and the transition to Phase II block may occur at lower cumulative doses; the RSI dose may be modestly reduced (some practitioners use 1.0 to 1.2 mg/kg rather than 1.5 mg/kg). For non-depolarizing agents like rocuronium, the competitive block is enhanced — less acetylcholine is available to compete with the blocking agent, shifting the dose-response curve leftward and requiring lower maintenance doses with longer dosing intervals. Critically, this patient is receiving ongoing magnesium infusion throughout the procedure and into the postoperative period; residual block from potentiated rocuronium in the presence of continued magnesium creates real risk of respiratory failure at extubation. Quantitative train-of-four monitoring is not optional in this patient — it is essential.

Option A: Option A is incorrect because progesterone does not upregulate presynaptic calcium channels to counteract magnesium; the interaction is pharmacologically real and clinically significant at therapeutic magnesium levels in pregnant patients.
Option B: Option B is incorrect because magnesium's primary mechanism is presynaptic (reducing acetylcholine release), not postjunctional receptor occupancy competitive with succinylcholine; increasing the succinylcholine dose to displace magnesium from receptors is based on an incorrect mechanistic premise.
Option C: Option C is incorrect because succinylcholine continuous infusion for a 30 to 60 minute surgical procedure is not appropriate practice — it risks Phase II block, and magnesium does interact with succinylcholine pharmacology; the premise that succinylcholine is unaffected by magnesium is incorrect.
Option E: Option E is incorrect because succinylcholine is also potentiated by magnesium — the presynaptic reduction in acetylcholine release affects the balance of agonist versus depolarizing blocker even for succinylcholine, and dose reduction is appropriate for both classes.

6. A previously healthy 5-year-old boy undergoes elective tonsillectomy. He has no known medical history, and his preoperative assessment is unremarkable. Succinylcholine 2 mg/kg is administered for intubation. Within 4 minutes, the anesthesiologist notes masseter spasm, rapidly rising end-tidal CO2, peaked T-waves on the ECG, and the patient develops ventricular fibrillation. Serum potassium drawn stat returns at 8.9 mEq/L. Serum creatine kinase drawn 30 minutes later is markedly elevated at 22,000 U/L. Resuscitation is successful. Subsequent genetic testing reveals a dystrophin gene deletion consistent with Duchenne muscular dystrophy. Which of the following correctly explains the mechanism of the cardiac arrest and the pathophysiological sequence in this patient?

A) The cardiac arrest resulted from succinylcholine-triggered malignant hyperthermia — dystrophin deficiency causes structural instability of the sarcoplasmic reticulum membrane, making the ryanodine receptor abnormally sensitive to succinylcholine activation; the masseter spasm represents the first manifestation of pathological SR calcium release, and the potassium elevation is a consequence of the resulting rhabdomyolysis rather than a direct cause of the arrhythmia.
B) The cardiac arrest resulted from succinylcholine-induced acute rhabdomyolysis and hyperkalemia in a child with undiagnosed Duchenne muscular dystrophy — dystrophin deficiency renders the sarcolemmal membrane structurally fragile; when succinylcholine triggers depolarization and fasciculations, the mechanical stress on the fragile dystrophin-deficient membrane causes acute membrane disruption, massive intracellular potassium and myoglobin release, and the resulting hyperkalemia of 8.9 mEq/L produced peaked T-waves and ventricular fibrillation; the markedly elevated creatine kinase confirms the rhabdomyolytic mechanism.
C) The cardiac arrest resulted from succinylcholine-induced extrajunctional receptor upregulation that occurs acutely within minutes of succinylcholine administration in genetically susceptible pediatric patients — children with dystrophinopathy upregulate extrajunctional receptors within 3 to 4 minutes of succinylcholine exposure as a rapid pharmacogenetic response, producing the massive potassium efflux seen; this distinguishes the dystrophinopathy mechanism from the delayed upregulation seen in denervation injuries.
D) The cardiac arrest resulted from pseudocholinesterase deficiency associated with the dystrophin gene mutation — the BCHE gene locus is located on the X chromosome near the dystrophin gene and is frequently co-deleted in patients with large dystrophin deletions; absent pseudocholinesterase produced scoline apnea with Phase II block, and the prolonged depolarization of Phase II block caused massive potassium efflux and the observed arrhythmia.
E) The cardiac arrest resulted from a direct cardiotoxic effect of succinylcholine at the high pediatric dose of 2 mg/kg — at doses above 1.8 mg/kg in children, succinylcholine reaches concentrations sufficient to directly block cardiac nicotinic receptors in the sinoatrial and atrioventricular nodes, producing conduction block; the simultaneous hyperkalemia from normal junctional potassium efflux at this high dose exceeded the cardiac threshold in a 5-year-old with proportionally lower total potassium distribution volume.

ANSWER: B

Rationale:

This question asked you to identify the mechanism of succinylcholine-induced cardiac arrest in a child with undiagnosed Duchenne muscular dystrophy. Duchenne muscular dystrophy results from absence of dystrophin — a large structural protein that connects the intracellular actin cytoskeleton to the extracellular matrix via the dystrophin-associated protein complex, maintaining the mechanical integrity of the sarcolemmal membrane during contraction. In the absence of dystrophin, the sarcolemma is structurally fragile. When succinylcholine produces the depolarizing fasciculations and the ion fluxes associated with activation of the entire muscle surface, the mechanical forces on the already-fragile dystrophin-deficient membrane cause acute sarcolemmal disruption. This produces massive simultaneous efflux of intracellular potassium and myoglobin into the circulation — a direct pharmacologically triggered acute rhabdomyolysis. The resulting hyperkalemia (here 8.9 mEq/L) produces the characteristic ECG changes of peaked T-waves and ultimately ventricular fibrillation. The masseter spasm in this patient may represent early rigidity from the acute rhabdomyolytic process in masseter muscle. The markedly elevated creatine kinase confirms widespread muscle membrane disruption. Critically, Duchenne muscular dystrophy is frequently undiagnosed at age 5 — clinical features such as Gowers' sign, calf pseudohypertrophy, and elevated baseline CK may not yet have been identified. This unpredictability is the pharmacological basis for the relative contraindication of succinylcholine in routine pediatric elective intubation.

Option A: Option A is incorrect because while the presentation has some overlap with malignant hyperthermia, the mechanism is distinct — MH involves ryanodine receptor-mediated SR calcium dysregulation and is treated with dantrolene; DMD-related succinylcholine toxicity is a membrane integrity and rhabdomyolysis/hyperkalemia syndrome; the primary arrhythmia driver is potassium, not calcium.
Option C: Option C is incorrect because extrajunctional receptor upregulation is a time-dependent process that requires days to weeks to develop — it cannot be acutely induced within minutes by succinylcholine administration; the mechanism in DMD is membrane fragility and acute rhabdomyolysis, not rapid receptor upregulation.
Option D: Option D is incorrect because the BCHE gene encoding pseudocholinesterase is located on chromosome 3, not on the X chromosome near the dystrophin locus; pseudocholinesterase deficiency does not co-segregate with dystrophin mutations; the mechanism described is pharmacologically incorrect.
Option E: Option E is incorrect because succinylcholine does not directly block cardiac nicotinic receptors to cause conduction block at any clinical dose; its cardiac effect is muscarinic (bradycardia), not nicotinic conduction block; and normal junctional potassium efflux from a standard succinylcholine dose produces only a 0.5 mEq/L rise, not the 8.9 mEq/L observed.

7. A 54-year-old man is in the post-anesthesia care unit following a 90-minute laparoscopic colectomy. He received rocuronium 0.6 mg/kg at induction and a maintenance dose of 0.15 mg/kg 40 minutes into the procedure. He was given neostigmine 0.05 mg/kg with glycopyrrolate at the end of the case when his train-of-four count was 2 with significant fade. He is now extubated but hypoxic at SpO₂ 86% on 6 L/min nasal cannula. He is awake, breathing spontaneously with a tidal volume of 420 mL, but cannot lift his head from the pillow for more than 2 seconds and is drooling with pooling of secretions visibly above his larynx on exam. Quantitative acceleromyography shows a TOF ratio of 0.65. Which of the following correctly identifies the problem and the appropriate pharmacological intervention?

A) This patient has adequate neuromuscular recovery — a TOF ratio of 0.65 with spontaneous breathing and acceptable tidal volume confirms sufficient diaphragmatic function; the hypoxia and secretion pooling represent post-extubation laryngeal edema from the intubation, and the appropriate management is supplemental oxygen escalation, head elevation, and nebulized racemic epinephrine rather than pharmacological neuromuscular reversal.
B) This patient requires re-intubation immediately — a TOF ratio of 0.65 indicates deep neuromuscular block with insufficient diaphragmatic reserve to sustain spontaneous ventilation; the 420 mL tidal volume is below the minimum required for adequate gas exchange, and no reversal agent will act quickly enough to prevent respiratory failure; airway control must be secured before pharmacological reversal is attempted.
C) This patient should receive additional neostigmine 0.07 mg/kg — neostigmine was underdosed at the 0.05 mg/kg given at the end of the procedure; the maximum dose of 0.07 mg/kg will generate sufficient additional acetylcholine to overcome the residual rocuronium block at a TOF ratio of 0.65, and this dose should fully restore neuromuscular function within 5 minutes; glycopyrrolate co-administration is not needed for a second dose because the first dose has already established adequate muscarinic receptor saturation.
D) This patient should receive atropine 0.5 mg intravenously — the secretion pooling and drooling indicate excessive muscarinic stimulation from an overdose of neostigmine; the weak head lift reflects central nervous system sedation from residual anesthetic rather than residual neuromuscular block, and the hypoxia will resolve once excessive bronchospasm from muscarinic overstimulation is treated with anticholinergic therapy.
E) This patient has clinically significant residual neuromuscular block — a TOF ratio of 0.65 is well below the 0.9 threshold required for safe extubation; the neostigmine given earlier was insufficient because it cannot reliably reverse block to a TOF ratio above 0.9 when the initial TOF count was only 2 with significant fade; sugammadex 2 mg/kg should be administered now, as this dose is appropriate for moderate block (TOF count ≥2), and quantitative monitoring should confirm TOF ratio above 0.9 before the patient is considered safe; the pharyngeal dysfunction causing secretion pooling and the hypoxia will resolve as neuromuscular function is restored.

ANSWER: E

Rationale:

This question asked you to recognize residual neuromuscular block in a symptomatic post-extubation patient and select the correct pharmacological intervention. This patient demonstrates the classic clinical picture of residual neuromuscular blockade at a TOF ratio of 0.65: he is breathing spontaneously (the diaphragm has some function at this ratio) but cannot sustain head lift for more than 2 seconds (indicating inadequate axial and accessory muscle function), has pooling secretions above the larynx (indicating pharyngeal and upper esophageal sphincter dysfunction — muscles that require TOF ratio ≥0.9 to function normally), and is hypoxic (from upper airway obstruction and aspiration of pooled secretions). The neostigmine given at the end of the case was given when TOF count was 2 with significant fade — an insufficient level of spontaneous recovery for reliable neostigmine reversal (TOF count of at least 2 is necessary but fade indicates incomplete recovery; ideally spontaneous recovery to T2 reappearance is established before neostigmine). Neostigmine has a ceiling effect and cannot reliably drive TOF ratio to ≥0.9 from a low starting point. Sugammadex 2 mg/kg is the appropriate dose for moderate block (TOF count ≥2 with fade) and will reliably restore full neuromuscular function — TOF ratio above 0.9 — within 5 minutes, resolving the pharyngeal dysfunction and allowing secretion clearance.

Option A: Option A is incorrect because a TOF ratio of 0.65 is not adequate recovery — it is clearly below the 0.9 threshold and the clinical findings of secretion pooling and weak head lift confirm pharmacologically significant residual block, not laryngeal edema.
Option B: Option B is incorrect because re-intubation is not yet indicated — the patient is awake, protecting his airway partially, and has a specific pharmacological solution available; sugammadex can reverse the block rapidly without the added risk and trauma of reintubation in this setting.
Option C: Option C is incorrect because neostigmine has a pharmacological ceiling and cannot reliably achieve TOF ratio ≥0.9 at this depth of residual block regardless of dose; administering more neostigmine when it has already failed to produce adequate reversal will not solve the problem and may produce excessive muscarinic effects.
Option D: Option D is incorrect because the secretion pooling and drooling are not from muscarinic overdose — they reflect pharyngeal muscle weakness from residual neuromuscular block; the weak head lift further confirms residual neuromuscular impairment rather than sedation or muscarinic excess.

8. A 68-year-old woman with open-angle glaucoma has been using echothiophate iodide 0.125% ophthalmic drops twice daily for 8 months to control her intraocular pressure. She is scheduled for cataract surgery under general anesthesia and the anesthesiologist, unaware of the echothiophate, administers succinylcholine 1.5 mg/kg for intubation. Two and a half hours later, the patient remains apneic with a train-of-four count of zero. The ophthalmologist confirms the echothiophate use after finding the bottle in the patient's bag. Which of the following correctly describes the mechanism of this prolonged block and the appropriate management?

A) Echothiophate is a long-acting organophosphate that irreversibly inhibits cholinesterase enzymes system-wide, including plasma pseudocholinesterase, through covalent phosphorylation of the enzyme's active serine residue; despite topical ophthalmic administration, sufficient systemic absorption occurs via nasolacrimal drainage and conjunctival vessels to produce near-complete inhibition of plasma pseudocholinesterase throughout the body; with pseudocholinesterase activity abolished, succinylcholine cannot be hydrolyzed and accumulates for hours; management is entirely supportive — maintain mechanical ventilation and adequate sedation until succinylcholine is cleared by very slow non-enzymatic degradation; neostigmine must not be given as it will further inhibit any residual pseudocholinesterase and prolong the block.
B) Echothiophate produced the prolonged block through a competitive inhibition of pseudocholinesterase that is reversible with pralidoxime (2-PAM) administration — pralidoxime reactivates the echothiophate-inhibited enzyme by cleaving the phosphoester bond within 30 to 60 minutes if given before enzyme aging occurs; in this patient who is still within the reactivation window, pralidoxime 1 to 2 g intravenously followed by atropine will restore pseudocholinesterase activity and allow succinylcholine to be hydrolyzed within 90 minutes.
C) Echothiophate inhibits hepatic cytochrome P450 2D6, which is responsible for a minor secondary hydrolysis pathway for succinylcholine that becomes dominant when pseudocholinesterase activity falls below 20% of normal; with both pathways inhibited, the patient should receive fresh frozen plasma containing normal pseudocholinesterase as the primary treatment to restore hydrolysis capacity within 20 to 30 minutes.
D) Echothiophate's systemic effects are limited to inhibition of synaptic acetylcholinesterase rather than plasma pseudocholinesterase — the prolonged block reflects elevated synaptic acetylcholine from acetylcholinesterase inhibition, which paradoxically stabilizes the succinylcholine-depolarized end plate in a permanent Phase II configuration; neostigmine is indicated to restore Phase I block characteristics before spontaneous recovery can proceed.
E) Echothiophate inhibits plasma pseudocholinesterase by a reversible competitive mechanism, temporarily reducing enzyme activity to approximately 15 to 20% of normal; at this residual activity level, succinylcholine hydrolysis is slowed proportionally, extending duration to approximately 30 to 45 minutes; the 2.5-hour block in this patient indicates a co-existing genetic pseudocholinesterase deficiency, and the appropriate investigation is a dibucaine number to characterize the underlying genotype.

ANSWER: A

Rationale:

This question asked you to identify the mechanism of echothiophate-induced prolonged succinylcholine block and specify the correct management, including the critical prohibition on neostigmine. Echothiophate iodide is a long-acting organophosphate cholinesterase inhibitor that forms a covalent phosphoester bond with the active site serine of cholinesterase enzymes — an irreversible inhibition under clinical conditions. Although administered as ophthalmic drops to the conjunctival sac, a clinically significant fraction is absorbed systemically through the nasolacrimal drainage system (bypassing conjunctival barriers) and through the highly vascularized conjunctival tissue. After 8 months of twice-daily use, plasma pseudocholinesterase activity may be reduced to near zero throughout the body. When succinylcholine is administered, it cannot be hydrolyzed by the inactivated pseudocholinesterase and accumulates in the plasma for hours — producing a clinical picture identical to homozygous genetic pseudocholinesterase deficiency (scoline apnea). The correct management is entirely supportive: maintain sedation (the patient is aware and paralyzed — a critical consideration), continue mechanical ventilation, and wait for very slow non-enzymatic degradation of succinylcholine. Neostigmine is absolutely contraindicated — it is itself a cholinesterase inhibitor that further suppresses any residual pseudocholinesterase activity, prolonging the block rather than reversing it. Recovery of pseudocholinesterase activity requires synthesis of new enzyme over weeks.

Option B: Option B is incorrect because pralidoxime (oxime reactivators) is used for acute organophosphate poisoning in the context of nerve agent or pesticide exposure; echothiophate-inhibited enzyme in chronic ophthalmic use is in an aged state not suitable for pralidoxime reactivation in most cases, and this is not the standard management for succinylcholine apnea from echothiophate.
Option C: Option C is incorrect because succinylcholine is not metabolized by CYP2D6; its hydrolysis is by plasma pseudocholinesterase only, and fresh frozen plasma, while theoretically containing donor pseudocholinesterase, is not standard management for this condition and carries transfusion risks.
Option D: Option D is incorrect because echothiophate inhibits both acetylcholinesterase and pseudocholinesterase, not only synaptic acetylcholinesterase; the mechanism of succinylcholine apnea is pseudocholinesterase inhibition preventing hydrolysis, not Phase II stabilization by elevated acetylcholine; and neostigmine is specifically contraindicated.
Option E: Option E is incorrect because echothiophate produces irreversible, not reversible competitive, cholinesterase inhibition; a 2.5-hour block after 8 months of echothiophate use is entirely explained by the organophosphate inhibition alone without requiring a genetic pseudocholinesterase deficiency.

9. A 66-year-old man with end-stage renal disease on hemodialysis three times weekly and known ischemic cardiomyopathy with an ejection fraction of 35% requires neuromuscular blockade for a 2-hour arteriovenous fistula revision. His resting heart rate is 82 beats per minute on his current medications. The anesthesiologist considers pancuronium 0.1 mg/kg but decides against it. Which of the following correctly identifies the two specific pharmacological liabilities of pancuronium that make it inappropriate for this patient, and names the preferred alternative?

A) Pancuronium is inappropriate because it undergoes extensive Hofmann elimination producing laudanosine, and in a patient with end-stage renal disease the impaired laudanosine clearance produces CNS excitation and potential seizures; additionally, pancuronium releases histamine at standard intubating doses, which is dangerous in a patient with low ejection fraction; cisatracurium is preferred because it generates less laudanosine per milligram than atracurium and releases no histamine.
B) Pancuronium is inappropriate because it is a benzylisoquinolinium with significant histamine-releasing properties that would produce dangerous vasodilation in a patient with cardiomyopathy and marginal cardiac reserve; and its exclusively hepatic elimination makes its duration unpredictable in dialysis-dependent renal failure where hepatic blood flow is reduced; rocuronium with quantitative monitoring is preferred.
C) Pancuronium is inappropriate for this patient for two specific reasons: first, it is eliminated approximately 80% unchanged by the kidneys, and in a dialysis-dependent patient with minimal residual renal function, its clearance is severely impaired, producing markedly prolonged and unpredictable block well beyond the 60 to 90 minutes expected in a normal patient; second, it blocks cardiac muscarinic receptors and inhibits neuronal norepinephrine reuptake, producing tachycardia and mild blood pressure elevation that are poorly tolerated in a patient with ischemic cardiomyopathy, ejection fraction of 35%, and a resting heart rate already at 82 bpm; cisatracurium is the preferred agent — its Hofmann elimination is independent of renal function and it has minimal cardiovascular effects.
D) Pancuronium is inappropriate because its active 3-desacetyl metabolite accumulates in renal failure and has cardiovascular stimulant properties that raise heart rate by 15 to 20 bpm — a consequence that is dangerous in this patient's hemodynamic context; and its onset time of 4 to 5 minutes is too slow for the surgical positioning requirements of AV fistula revision; cisatracurium with its 2-minute onset and no active renally cleared metabolites is preferred.
E) Pancuronium is inappropriate because it is metabolized by plasma pseudocholinesterase, and dialysis-dependent patients have markedly reduced pseudocholinesterase activity due to impaired renal synthesis of the enzyme; additionally, its vagolytic properties produce tachycardia that increases myocardial oxygen demand; succinylcholine is preferred for this patient because its ultra-short duration ensures that any residual block resolves before the 2-hour procedure concludes.

ANSWER: C

Rationale:

This question asked you to identify the two specific pharmacological liabilities of pancuronium in a patient with dialysis-dependent renal failure and ischemic cardiomyopathy, and to name the appropriate alternative. The two converging problems with pancuronium in this patient are elimination and cardiovascular effects. First, pancuronium is eliminated approximately 80% unchanged by the kidneys via glomerular filtration and renal tubular secretion. In a patient with end-stage renal disease and minimal residual renal function, pancuronium clearance is severely impaired — a 60 to 90 minute drug under normal conditions can produce block lasting many hours, which is both clinically inconvenient and difficult to manage. Second, pancuronium blocks cardiac muscarinic M2 receptors (vagolytic tachycardia) and inhibits neuronal norepinephrine reuptake (sympathomimetic mild hypertension and tachycardia). In a patient with ischemic cardiomyopathy, ejection fraction of 35%, and a resting heart rate already at 82 bpm — indicating a heart working near its chronotropic and inotropic reserve — further heart rate elevation from pancuronium increases myocardial oxygen demand and reduces diastolic filling time, creating genuine risk of perioperative ischemia. Cisatracurium addresses both problems: its Hofmann elimination is entirely organ-independent (predictable duration regardless of dialysis dependence) and it has minimal direct cardiovascular effects at clinical doses.

Option A: Option A is incorrect because pancuronium is an aminosteroid, not a benzylisoquinolinium — it does not undergo Hofmann elimination and does not produce laudanosine; laudanosine is produced by atracurium and cisatracurium.
Option B: Option B is incorrect because pancuronium is an aminosteroid, not a benzylisoquinolinium — it does not release histamine; and its elimination is renal, not hepatic.
Option D: Option D is incorrect because pancuronium does not have a 3-desacetyl metabolite with cardiovascular stimulant properties; the 3-desacetyl active metabolite is specific to vecuronium; and pancuronium's onset at 0.1 mg/kg is approximately 3 to 4 minutes, not 4 to 5.
Option E: Option E is incorrect because pancuronium is not metabolized by plasma pseudocholinesterase; it is an aminosteroid eliminated by renal excretion; pseudocholinesterase is not renally synthesized; and succinylcholine is not appropriate for 2-hour surgical maintenance.

10. A 19-year-old man undergoes elective knee arthroscopy under general anesthesia with sevoflurane and succinylcholine for intubation. Fifteen minutes into the procedure the anesthesiologist notes: end-tidal CO2 rising from 38 to 67 mmHg despite unchanged ventilator settings; temperature 39.8°C and rising; generalized muscle rigidity palpable across the jaw and extremities; heart rate 138 bpm; and metabolic acidosis with pH 7.18 on arterial blood gas. Serum potassium is 6.4 mEq/L. Malignant hyperthermia is suspected. Which of the following correctly describes the immediate pharmacological management priorities?

A) Administer neostigmine 0.07 mg/kg with glycopyrrolate immediately — the hypercarbia and rigidity indicate residual succinylcholine-induced Phase II block compounded by sevoflurane-induced neuromuscular sensitization; increasing acetylcholine concentration will competitively displace succinylcholine from nicotinic receptors, reversing the rigidity and reducing CO2 production from the hypermetabolic muscle activity.
B) Administer sugammadex 16 mg/kg immediately — succinylcholine at intubating doses produces profound block that has paradoxically transitioned to a hyperexcitatory Phase II state in this patient, and encapsulation of the residual succinylcholine by sugammadex will terminate the calcium dysregulation driving the hyperthermia and rigidity within 3 minutes.
C) Administer sodium bicarbonate 1 to 2 mEq/kg intravenously as the primary intervention — the metabolic acidosis is the driver of both the cardiac arrhythmia risk and the muscle rigidity, because acidosis impairs SERCA pump function and calcium reuptake into the sarcoplasmic reticulum; correcting the pH will normalize calcium handling and resolve the crisis before dantrolene is needed.
D) Immediately discontinue sevoflurane and switch to a total intravenous anesthetic technique; administer dantrolene 2.5 mg/kg intravenously and repeat every 5 minutes until the crisis is controlled, with a total dose potentially exceeding 10 mg/kg; initiate active cooling; treat the hyperkalemia; and notify the MH hotline — dantrolene directly inhibits ryanodine receptor-mediated sarcoplasmic reticulum calcium release, addressing the primary molecular defect driving the hypermetabolic crisis.
E) Administer propofol 2 mg/kg intravenously to achieve deep general anesthesia — sevoflurane at its current concentration is providing insufficient depth of anesthesia, causing awareness-related sympathetic activation that mimics MH; deepening anesthesia with a non-triggering intravenous agent will resolve the tachycardia, hypercarbia, and rigidity within 90 seconds, and dantrolene should be withheld until a formal temperature of 40°C is confirmed on central thermometry.

ANSWER: D

Rationale:

This question asked you to identify the immediate pharmacological management priorities in a patient with an acute malignant hyperthermia crisis. MH is a pharmacogenetic hypermetabolic emergency caused by uncontrolled calcium release from the sarcoplasmic reticulum in skeletal muscle, triggered by volatile anesthetic agents (sevoflurane, halothane, isoflurane, desflurane) and succinylcholine in patients with RYR1 mutations. The clinical picture in this patient — rapidly rising end-tidal CO2, hyperthermia, generalized rigidity, tachycardia, acidosis, and hyperkalemia — is a textbook MH crisis. The immediate management priorities are: first, eliminate all triggering agents by discontinuing sevoflurane and switching to a non-triggering total intravenous anesthetic technique (propofol-based); second, administer dantrolene — the specific antidote — at 2.5 mg/kg IV repeated every 5 minutes until the crisis is controlled, with total doses potentially exceeding 10 mg/kg; dantrolene inhibits the ryanodine receptor calcium release channel, directly addressing the primary molecular defect; third, initiate active cooling measures; fourth, treat the hyperkalemia and acidosis with supportive measures. Speed is critical — MH without dantrolene is rapidly fatal.

Option A: Option A is incorrect because neostigmine has no mechanism of action relevant to MH — the crisis is caused by sarcoplasmic reticulum calcium dysregulation, not by cholinesterase activity or succinylcholine receptor occupancy; neostigmine cannot treat MH.
Option B: Option B is incorrect because sugammadex encapsulates aminosteroid non-depolarizing agents (rocuronium, vecuronium) and has no mechanism relevant to succinylcholine or to the ryanodine receptor calcium dysregulation driving MH; succinylcholine is not reversed by sugammadex.
Option C: Option C is incorrect because sodium bicarbonate is supportive therapy for the metabolic acidosis that develops during MH, not the primary intervention; correcting pH does not address the underlying calcium release pathology and withholding dantrolene to wait for bicarbonate effect would be fatal.
Option E: Option E is incorrect because this is not anesthetic awareness — the clinical triad of rigidity, hyperthermia, and hypercarbia with rising potassium represents a genuine pharmacogenetic metabolic crisis requiring immediate dantrolene; deepening anesthesia with propofol without giving dantrolene delays life-saving treatment.

11. A 52-year-old woman undergoes exploratory laparotomy for perforated sigmoid diverticulitis. She received rocuronium 0.6 mg/kg at induction and a maintenance dose 35 minutes later. As the surgical team irrigates the peritoneal cavity with tobramycin solution for infection prophylaxis, the anesthesiologist notes the train-of-four count dropping from 3 to 0 within 8 minutes. At wound closure, she administers neostigmine 0.07 mg/kg with glycopyrrolate, but 15 minutes later the TOF count is only 1 with persistent deep fade. Which of the following correctly explains the inadequate neostigmine response and identifies the most appropriate additional pharmacological intervention?

A) The inadequate neostigmine response confirms that the patient has unmasked pseudocholinesterase deficiency — tobramycin inhibits plasma pseudocholinesterase, revealing a heterozygous deficiency that was compensated under normal conditions; the tobramycin-pseudocholinesterase interaction has converted the rocuronium block to a mixed depolarizing-non-depolarizing state that neostigmine cannot fully reverse; the appropriate intervention is fresh frozen plasma to replenish pseudocholinesterase activity.
B) Tobramycin has potentiated the existing rocuronium block by inhibiting presynaptic voltage-gated calcium channels at the motor nerve terminal, reducing acetylcholine release; neostigmine can only prolong the action of released acetylcholine — it cannot compensate for severely reduced acetylcholine release caused by calcium channel inhibition; sugammadex 4 mg/kg is the most appropriate intervention because it directly removes rocuronium from plasma and the NMJ by encapsulation, bypassing the presynaptic problem entirely and reliably restoring neuromuscular function regardless of how little acetylcholine is available.
C) The inadequate neostigmine response is expected — tobramycin competitively inhibits acetylcholinesterase in addition to its presynaptic effect, and the combined acetylcholinesterase inhibition from both neostigmine and tobramycin has paradoxically desensitized the end plate through excess acetylcholine accumulation; the appropriate intervention is atropine 2 mg to block the excess muscarinic activity followed by a 30-minute observation period for spontaneous recovery.
D) Tobramycin has produced its potentiation by directly alkylating the nicotinic acetylcholine receptor at the alpha subunit binding pocket, producing irreversible block at the occupied receptors; neostigmine reversal fails because the alkylated receptors cannot respond to increased acetylcholine; calcium gluconate is contraindicated because additional calcium influx into already-depolarized muscle fibers will worsen the alkylation damage.
E) The inadequate neostigmine response is consistent with tobramycin's mechanism of nicotinic receptor competitive antagonism — tobramycin occupies nAChR agonist binding sites with higher affinity than rocuronium, and because neostigmine reversal relies on acetylcholine competing with the blocking agent, the high-affinity tobramycin occupancy cannot be overcome by increased acetylcholine; the appropriate intervention is sugammadex 16 mg/kg, which encapsulates both rocuronium and tobramycin simultaneously.

ANSWER: B

Rationale:

This question asked you to explain why neostigmine failed in the setting of aminoglycoside-potentiated neuromuscular block and identify the pharmacologically correct additional intervention. Aminoglycoside antibiotics — tobramycin, gentamicin, neomycin — inhibit presynaptic voltage-gated calcium channels at the motor nerve terminal, reducing calcium influx during action potential depolarization and thereby decreasing the quantal content of acetylcholine released per nerve impulse. This presynaptic block operates in addition to the existing postsynaptic competitive block from rocuronium. Neostigmine's mechanism is acetylcholinesterase inhibition, which prolongs the action of whatever acetylcholine is released into the synapse. When presynaptic calcium channel inhibition by tobramycin has severely reduced the amount of acetylcholine available per impulse, neostigmine cannot compensate — it can slow breakdown of a small amount of acetylcholine, but it cannot increase release. The TOF count of 1 with persistent fade after maximum-dose neostigmine confirms this ceiling effect. Sugammadex 4 mg/kg (the dose for deep block with TOF count 0 and PTC ≥2, or escalated to 16 mg/kg if PTC is very low) bypasses the presynaptic problem entirely by removing rocuronium molecules from the plasma and NMJ through cyclodextrin encapsulation, eliminating the postsynaptic competitive antagonism regardless of how little acetylcholine is available. Calcium gluconate is a pharmacologically rational adjunct — it competes with tobramycin at presynaptic calcium channels, partially restoring acetylcholine release — but sugammadex is the primary definitive reversal strategy.

Option A: Option A is incorrect because tobramycin does not inhibit plasma pseudocholinesterase; rocuronium block is not a depolarizing or pseudocholinesterase-dependent process; and fresh frozen plasma is not a rational intervention for this mechanism.
Option C: Option C is incorrect because tobramycin does not inhibit acetylcholinesterase; the two agents have different sites of action and do not produce combined acetylcholinesterase inhibition; end-plate desensitization from acetylcholine excess is not the mechanism of inadequate neostigmine reversal here.
Option D: Option D is incorrect because tobramycin does not alkylate the nAChR; its mechanism is presynaptic voltage-gated calcium channel inhibition, not covalent receptor modification; and calcium gluconate is not contraindicated — it is pharmacologically rational as an adjunct because it competes at the presynaptic channel.
Option E: Option E is incorrect because tobramycin does not compete at nAChR agonist binding sites; its mechanism is presynaptic; and sugammadex does not encapsulate tobramycin — it encapsulates only steroidal aminosteroid NMBD molecules through its cyclodextrin cavity; the 16 mg/kg dose claim for combined encapsulation is pharmacologically incorrect.